Abstract
AbstractHigh rates of mortality in non-small cell lung cancer lung cancer is due to inherent and acquired resistance to systemic therapies and subsequent metastatic burden. Metastasis is supported by suppression of the immune system at secondary organs and within the circulation. Modulation of the immune system is now being exploited as a therapeutic target with immune checkpoint inhibitors. The tracking of therapeutic efficacy in a real-time can be achieved with liquid biopsy, and evaluation of circulating tumour cells and the associated immune cells. A stable liquid biopsy biomarker for non-small cell lung cancer lung cancer has yet to be approved for clinical use. We performed a cross-sectional single-site study, and collected liquid biopsies from patients diagnosed with early, locally advanced, or metastatic lung cancer, undergoing surgery, or systemic therapy (chemotherapy/checkpoint inhibitors). Evaluation of overall circulating tumour cell counts, or cluster counts did not correlate with patient outcome. Interestingly, the numbers of Pan cytokeratin positive circulating tumour cells engulfed by tumour associated monocytes correlated strongly with patient outcome independent of circulating tumour cell counts and the use of checkpoint inhibitors. We suggest that Pan cytokeratin staining within monocytes is an important indicator of tumour-associated inflammation post-therapy and an effective biomarker with strong prognostic capability for patient outcome.
Funder
The University of Queensland
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594
2. Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S et al (2022) Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer 21:1–22
3. Cho BC, Loong HHF, Tsai CM, Teo MLP, Kim HR, Lim SM et al (2022) Genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumor DNA (ctDNA) in clinical practice. Curr Oncol 29(3):2154–2164
4. Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR et al (2021) Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun 12(1):1–14
5. Fernandes MGO, Cruz-Martins N, Machado JC, Costa JL, Hespanhol V (2021) The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. Cancer Cell Int 21(1):1–19
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Liquid Biopsy in the Clinical Management of Cancers;International Journal of Molecular Sciences;2024-08-06